LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising.

Pony AI Inc. (PONY) reported 3Q25 revenue of $25.44M, up 72% YoY, driven by strong Robotaxi and Licensing & Applications growth. PONY's Robotaxi segment saw fare-charging rides surge 200%+, with Licensing & Applications revenue up 354%, boosting gross margin to 18.4%. Management targets 1,000 vehicles by year-end and 3,000 by 2026, supporting a forecast of 2-3x revenue growth over two years.

Cost discipline is firmly back, with C1/t converging to guidance and restoring confidence in Vale's operational execution. Seasonal and geopolitical tailwinds keep iron ore supported near term, while Vale's efficiency cushions any medium-term softness. Legacy risks from Brumadinho and Samarco are becoming contained, improving visibility for FCF and extraordinary dividends.

LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Primo Brands Corporation (“Primo” or “the Company”) (NYSE: PRMB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of PRMB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

On Holding's Q3 strength reinforces the growth story. On delivered a clear beat across sales, gross margin, and EBITDA. Updated guidance, structural margin improvements, and strong DTC traction support higher confidence in the path to the 2028 outlook. Despite a share de-rating, ONON continues to execute at a premium level; we maintain our constructive stance as the market underestimates the brand's multi-category and multi-sport potential.

U.S. sales of Korean cosmetics, known as K-beauty, are expected to exceed $2 billion in 2025, up 37% from last year, according to a NielsenIQ report. Retailers including Ulta, Sephora, Walmart and Costco are in a turf war to capitalize on the fast-growing Korean cosmetics market.

LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Freeport-McMoRan Inc. (“Freeport” or “the Company”) (NYSE: FCX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of FCX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

STOCKHOLM--(BUSINESS WIRE)--Klarna, the global digital bank and flexible payments provider, today announces a new multi-market partnership with Lufthansa Group, Europe's leading airline group. The new agreement is facilitated by Klarna's integration with Adyen, the financial technology platform of choice for leading businesses. From November, Lufthansa Group customers will be able to choose Klarna's flexible payment options at checkout when booking travel experiences. This new integration gives.

Morgan Stanley (MS) whose price grew 18% since my bullish call last winter, is being slightly pulled back to a hold but remains a strong dividend income idea. Q3 results showed net new client inflows, momentum in advisory work, and strong A-level credit ratings across the board, against a challenging macro backdrop in 2025. The stock appears somewhat overvalued to its peer average, with future upside forecasts being minimal.

Gold traded quietly in thin Thanksgiving conditions, holding near resistance at $4,200. A pullback toward $4,000 could be healthy, while a breakout above $4,200 would target $4,400.

Barrick Mining Corporation (B) remains a top gold mining pick, with strong financials, Tier One gold and copper assets, and a robust global project pipeline. B delivered record Q3 cash flow, is advancing non-core asset divestitures, and maintains a solid balance sheet with improving net cash and dividend policy. Key catalysts include resolution of Mali disputes, Elliott Management's activist stake, CEO transition, and major projects like Reko Diq and Lumwana expansion advancing.

LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Firefly Aerospace Inc. (“Firefly” or “the Company”) (NASDAQ: FLY) for violations of the federal securities laws. Shareholders who purchased shares of FLY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Investors are concerned by Meta's heavy spending. Yet, Meta's base advertising business is thriving.

Stocks are having their best Thanksgiving week since 2012 but as Americans around the country rush to put their turkeys in the oven even more market gains could be heating up.

Energy Transfer remains a top opportunity in the midstream sector, supported by strong fee-based operations and strategic partnerships. ET's Q3 earnings showed resilience, with stable core EBITDA despite commodity price weakness and a distribution increase supported by a robust coverage ratio. The Oracle and Voltagrid deal positions ET at the forefront of AI-driven energy demand, enhancing asset utilization and long-term growth prospects.

Praxis Precision Medicines, Inc. is upgraded to a Strong Buy, driven by pipeline progress and positive phase 3 data for Ulixacaltamide in Essential Tremor. PRAX's Ulixacaltamide achieved primary endpoints in two phase 3 studies, positioning it as the first potential FDA-approved therapy for Essential Tremor, targeting a large unmet market. Upcoming PRAX catalysts include a pre-NDA meeting with the FDA in Q4 2025 and a potential NDA filing for Ulixacaltamide in 2026, alongside advancing late-stage trials for Vormatrigine and Relutrigine.

Dell Technologies (DELL) shares jumped Wednesday after the PC maker hiked its outlook, pointing to a boost from AI-driven demand.

Shares of Oscar Health (OSCR) jumped Wednesday, the latest big gain for the health insurer after Piper Sandler analysts upgraded their rating of the stock in a recent note to clients.

ISS Highlights Cannae's Poor Total Shareholder Return and Operating Performance, Clear Lack of Independence from Bill Foley and Damaging Corporate Governance Deficiencies